Xencor (XNCR) Expected to Post Quarterly Earnings on Wednesday

Xencor (NASDAQ:XNCR) is projected to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Xencor to post earnings of ($0.3341) per share and revenue of $63.00 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.51. The company had revenue of $51.22 million for the quarter, compared to analysts’ expectations of $18.89 million. During the same period in the prior year, the firm posted ($0.41) EPS. The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. On average, analysts expect Xencor to post ($3.05) EPS for the current fiscal year and ($3.31) EPS for the next fiscal year.

Xencor Stock Performance

Shares of Xencor stock opened at $29.99 on Wednesday. Xencor has a 12-month low of $10.38 and a 12-month high of $33.60. The firm’s 50 day simple moving average is $25.56 and its two-hundred day simple moving average is $16.73.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. Wells Fargo & Company lifted their price target on Xencor from $30.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday. JPMorgan Chase & Co. boosted their price target on Xencor from $14.00 to $21.00 and gave the company a “neutral” rating in a research note on Thursday, September 3rd. Barclays set a $45.00 price objective on Xencor and gave the company an “overweight” rating in a report on Monday. Finally, Bank of America raised their price objective on Xencor from $20.00 to $26.00 and gave the stock a “neutral” rating in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Xencor presently has a consensus rating of “Moderate Buy” and an average target price of $39.33.

More Xencor News

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Updated Phase 1 data for XmAb819 showed a reported 45.5% response rate in heavily pretreated ccRCC patients, with coverage describing the antitumor activity as “impressive,” “unprecedented” and “profound.” Xencor plans to advance the program toward a late-stage trial. Xencor Reveals Updated Phase 1 XmAb819 Data and Projects Cash Runway Through 2029
• Positive Sentiment: The company said its cash resources are expected to fund operations through 2029, reducing near-term financing concerns as it develops XmAb819 and other pipeline programs. Cash Runway and Updated Data
• Positive Sentiment: Analyst sentiment strengthened following the data. Wedbush raised its price target from $30 to $45 and maintained an Outperform rating, while RBC increased its target from $20 to $43 and retained Outperform, though it continues to flag speculative risk. Wedbush Analyst Recommendation RBC Raises Price Target
• Neutral Sentiment: The response data are from a Phase 1 study, so durability, safety, comparative efficacy and confirmation in larger controlled trials remain important uncertainties. The stock is now near its 12-month high after a sharp rally, increasing sensitivity to follow-up data and profit-taking.
• Negative Sentiment: Xencor remains unprofitable, and analysts expect a loss for the full year. XmAb819’s potential FDA accelerated-approval pathway is not guaranteed; disappointing safety or efficacy results could weigh heavily on the shares.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.